Finally, Satapathy et al. [26] assessed the impact of 225Ac-PSMA on QoL of patients with mCRPC using the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 (NCCN-FACT-FPSI-17) questionnaire. The gene discussed is FOLH1; the disease is cancer.